Importer of Controlled Substances Application: Caligor Coghlan Pharma Services
Published Date: 11/26/2025
Notice
Summary
Caligor Coghlan Pharma Services wants to become an official importer of certain controlled substances, including some powerful drugs like LSD. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Importer Application for Schedule I Drugs
Caligor Coghlan Pharma Services applied on July 24, 2025 to be registered to import these Schedule I finished dosage units for clinical trials: lysergic acid diethylamide (LSD, code 7315), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431), dimethyltryptamine (DMT, code 7435), and psilocyn (code 7438). The company plans to import finished dosage units for use in clinical trials only, subject to approval under 21 U.S.C. 952(a)(2).
No Commercial Sale Import Authorization
The notice explicitly says authorization will not extend to import of FDA‑approved or non‑approved finished dosage forms for commercial sale. If you planned to import these drugs for commercial sale, this registration would not permit that activity.
Comment and Hearing Deadline: Dec 26, 2025
Registered bulk manufacturers of the affected drug classes, applicants, and other interested parties may submit electronic comments or objections, or file a written request for a hearing, on or before December 26, 2025. Comments must be submitted through Regulations.gov; hearing requests must be filed with DEA addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-21178, Importer of Controlled Substances Application: Siegfried Grafton, Inc.
Siegfried Grafton, Inc. wants to become an official importer of certain controlled substances like marijuana and gamma hydroxybutyric acid. People and companies involved can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
Next: 2025-21180, Importer of Controlled Substances Application: NSI Lab Solutions, LLC.
NSI Lab Solutions, LLC wants to become an official importer of certain controlled substances, including some strong drugs like 3-FMC and Cathinone. This affects companies involved in drug manufacturing and import, who can comment or request a hearing by December 26, 2025. No direct money changes yet, but this move could impact the drug supply chain and regulatory oversight.